Milrinone: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - " pt " to " patient ") |
No edit summary |
||
| Line 51: | Line 51: | ||
===Indication=== | ===Indication=== | ||
low cardiac output states due to impaired myocardial contractility | *low cardiac output states due to impaired myocardial contractility | ||
==See Also== | ==See Also== | ||
==References== | ==References== | ||
<references/> | |||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
Revision as of 06:48, 13 July 2017
General
- Type: Vasopressors
- Dosage Forms:
- Common Trade Names:
Adult Dosing
Dosing
- Normal renal function:
0.25 - 0.75 mcg/kg/min
- Creatinine clearance < 50mL/min, reduce infusion rate
Rate of Titration
- Q2H; slower titration rate if renal insufficiency
Pediatric Dosing
Special Populations
- Pregnancy Rating:
- Lactation:
- Renal Dosing
- Adult
- Pediatric
- Hepatic Dosing
- Adult
- Pediatric
Contraindications
- Allergy to class/drug
Adverse Reactions
- Tachyarrhythmias
- Hypotension
- Myocardial ischemia
Pharmacology
- Half-life:
- Metabolism:
- Excretion:
- Mechanism of Action:
Primary Receptor
- PDE-3 inhibitor
Relative Effects
- ↑HR
- ↑↑↑SV
- ↓SVR
Notes
- Can use as alternative to dobutamine in patients with cardiogenic shock and on b-blockers
- Causes pulmonary vasodilation, may be good choice in patients with RV failure
- ↑cAMP in cardiac myocytes and vascular smooth muscle, thereby ↑HR and ↑SV while decreasing ↓SVR
- Use with caution in patient with renal failure and hypovolemia
Indication
- low cardiac output states due to impaired myocardial contractility
